Search results
Mar 10, 2022 · Pioneering treatments for CNS diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.
- Who We Are
Atalanta is pioneering new treatment options for intractable...
- our science & focus
The common scaffold for our therapeutics enables effective...
- news
October 14, 2019. Nature Biotechnology “Two new startups,...
- Who We Are
Jan 11, 2021 · Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases. Founders are world-leading experts in RNA interference, including Nobel laureate Craig Mello. Company has assembled a first-class management team of industry veterans helmed by CEO Alicia Secor.
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D...
May 22, 2024 · BOSTON, May 22, 2024 -- ( BUSINESS WIRE )-- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the...
Aug 26, 2022 · Headquartered in Boston, Atalanta Therapeutics is developing new treatment options for neurodegenerative diseases and other central nervous system (CNS) disorders by utilizing its proprietary...
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases. Boston, Massachusetts, United States. 11-50. Series A. Private. heylink.me/link.indahjp/ 11,935. Highlights. Total Funding Amount. Unlock for free. Contacts 60. Employee Profiles 7. Investors 1. Similar Companies 14. Company Insights.
